Business Wire

Slate Asset Management Announces £50 Million Investment in UK-Based Vertical Farming Business, Eider VF Limited

25.5.2022 10:00:00 EEST | Business Wire | Press release

Share

Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has completed a £50 million investment in Eider VF Limited (“EVF”), a UK-based vertical farming business, through its Cities and Communities Impact Infrastructure Strategy.

Founded in 2016, EVF is a vertical farming business based in Birmingham, England that develops farms growing leafy produce to be sold to the UK mass market. EVF’s products are grown in standard warehouses that are augmented to house vertical farms, using standard industrial equipment to create environments in which the plants thrive. EVF has secured long-term partnership agreements with leading manufacturers and suppliers of leafy produce to the UK retail and food service markets.

Slate’s investment will be used to fund the construction of EVF’s first five facilities by 2024, which will be built adjacent to existing packing facilities, thereby significantly reducing transport costs. The facilities will be equipped to sustainably grow leafy produce 24/7, 365 days a year, significantly reducing wastewater, nutrient usage, and biohazard risk.

“Vertical farming aligns seamlessly with the focus of our Cities and Communities Impact Infrastructure Strategy and contributes to many of the United Nation’s Sustainable Development Goals, promoting more resource-efficient food production, reducing carbon emissions in the journey from farm to fork, and providing an alternative way of growing food that protects the environment and surrounding ecosystem,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “We’re very pleased to be launching into this sector with our investment in EVF, which is pioneering the commercialization and delivery of vertically farmed produce to the “mass” market in a sustainable and cost-efficient way.”

Mike Davies of EVF said: “Slate was the optimal partner for us in this phase of growth, given there are significant real estate and ESG components involved in the buildout and operations of our facilities. We look forward to working closely with Christian and leveraging the global institutional expertise of the broader Slate team to deploy our first facilities and ensure we are managing them in the most efficient and sustainable ways.”

Slate is an active investor in sustainable assets and technologies through its Cities and Communities Impact Infrastructure Strategy. The Strategy is focused on investments that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals, including technologies and assets that contribute to a more sustainable food manufacturing and supply chain.

Slate recently hired Jan Greenshaw, an Investment Associate, to support the continued growth of Slate’s Cities & Communities Impact Infrastructure Strategy. Greenshaw joined Slate in May 2022 from Queensland Investment Corporation, where he worked on the Global Infrastructure team.

This Transaction closed on 13 May 2022.

About Slate Asset Management
Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.

About Eider VF Limited
By growing crops so close to its customers, EVF is reducing the distance from farm to fork, slashing food miles, strengthening UK food security and limiting emissions while delivering more nutritious and delicious food.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Slate Asset Management

Investor Relations
ir@slateam.com

Press Inquiries
Karolina Kmiecik
Karolina@slateam.com

Eider VF Limited
ask@eider.ag

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release

The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye